Research

Fig. 1. We utilize genomics to identify the genetic basis by which Merkel cell carcinoma cells can be targeted by the patient’s own immune system. 

Our lab has two areas of research focus.

Computational Oncology.

  • We utilize genomics and orthogonal high dimensional assays to elucidate the molecular features of each patient’s cancer. We then perform iterative analyses across a disease cohort to identify molecular features that occur more often than expected by chance. We then functionally validate the putative drivers using human and mouse models.
  • We interrogate patient samples to identify molecular features that predict disease prognoses and responses to therapies.
  • The goal is to identify novel potentially curative therapeutic strategies for otherwise intractable diseases.

Immunogenomics.

  • We utilize genomics and orthogonal high dimensional assays to resolve the cellular and genetic mechanisms governing immune homeostasis.
  • These approaches have led to the following discoveries:
    • Novel skin-resident cells (coming soon!)
    • Novel molecular mechanisms governing T cell activation
    • Novel molecular mechanisms governing T cell differentiation
  • We leverage these discoveries to identify novel therapeutic strategies for inflammatory diseases and cancer.

“In God we trust, all others [must] have data.”
Bernard Fisher